HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test may predict breast cancer drug response
Knowledge-focused CompletedThis study explored whether a simple blood test measuring the neutrophil-to-lymphocyte ratio (NLR) can help predict how well women with advanced breast cancer respond to a common treatment (CDK4/6 inhibitors plus hormone therapy). Researchers followed 165 patients starting this t…
Matched conditions: HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Phase: NA • Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Real-World data reveals how breast cancer drugs perform outside the lab
Knowledge-focused CompletedThis study observed over 2,600 women in Germany with a common type of advanced breast cancer (HR+/HER2-). Researchers compared how long the cancer stayed under control when women started treatment with a drug combo (ribociclib plus hormone therapy) versus other hormone therapies …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC